New pathophysological relevant metabolic pathways in osteoporosis. Future innovative therapies?;Neue pathophysiologische stoffwechselwege in der osteoporose. Zukünftige innovative therapieansätze?

Zeitschrift fur Rheumatologie

Volumn 65, Issue 5, 2006, Pages 400-406

  Neumann, E ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

OPG; Osteoclastogenesis; Osteoporosis; RANK; RANKL

Indexed keywords

AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; DENUSOMAB; GLUCOCORTICOID; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; VITAMIN D; WNT PROTEIN;

ARTICLE; BONE MASS; BONE METABOLISM; BONE REMODELING; CELL ACTIVITY; CELL FUNCTION; CLINICAL TRIAL; FRACTURE REDUCTION; HUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT RESPONSE;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; HUMANS; OSTEOBLASTS; OSTEOCLASTS; OSTEOPOROSIS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 33749130659     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-006-0086-8     Document Type: Article

References (24)

1. Bord S, Ireland DC, Beavan SR, Compston JE (2003) The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone 32: 136-141
2. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423: 337-342
3. Catrina AI, af Klint E, Ernestam S et al. (2006) Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum 54: 76-81
4. Dobnig H, Hofbauer LC, Viereck V et al. (2006) Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int 17: 693-703
5. Ebeling PR (2006) Editorial: inhibin in bone - new tricks for an old dog. J Clin Endocrinol Metab 91: 1669-1670
6. Hofbauer LC (2006) Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG). Ann Endocrinol (Paris) 67: 139-141
7. Hofbauer LC, Schoppet M (2004) Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292: 490-495
8. Kamijo S, Nakajima A, Ikeda K et al. (2006) Amelioration of bone loss in collagen-induced arthritis by neutralizing anti-RANKL monoclonal antibody. Biochem Biophys Res Commun 347: 124-132
9. Kananen K, Volin L, Laitinen K et al. (2006) Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss? Osteoporos Int 17: 724-730
10. Kostenuik PJ (2005) Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 5: 618-625
11. Krishnan V, Bryant HU, Macdougald OA (2006) Regulation of bone mass by Wnt signaling. J Clin Invest 116: 1202-1209
12. Locklin RM, Khosla S, Turner RT, Riggs BL (2003) Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem 89: 180-190
13. Mazziotti G, Angeli A, Bilezikian JP et al. (2006) Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab 17: 144-149
14. McClung MR (2006) Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies. Curr Osteoporos Rep 4: 28-33
15. McClung MR, Lewiecki EM, Cohen SB et al. (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354: 821-831
16. Neumann E, Gay S, Muller-Ladner U (2005) The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: new insights from animal models. Arthritis Rheum 52: 2960-2967
17. Perrien DS, Achenbach SJ, Bledsoe SE et al. (2006) Bone turnover across the menopause transition: correlations with inhibins and follicle-stimulating hormone. J Clin Endocrinol Metab 91: 1848-1854
18. Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367: 2010-2018
19. Shevde NK, Bendixen AC, Dienger KM, Pike JW (2000) Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci U S A 97: 7829-7834
20. Spohn G, Schwarz K, Maurer P et al. (2005) Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles. J Immunol 175: 6211-6218
21. Srivastava S, Toraldo G, Weitzmann MN et al. (2001) Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. J Biol Chem 276: 8836-8840
22. Vis M, Haavardsholm EA, Haugeberg G et al. (2006) Evaluation of bone mineral density, bone metabolism, osteoprotegerin and RANKL serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis
23. Wada T, Nakashima T, Hiroshi N, Penninger JM (2006) RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 12: 17-25
24. Xu D, Wang S, Liu W et al. (2006) A novel receptor activator of NF-kappaB (RANK) cytoplasmic motif plays an essential role in osteoclastogenesis by committing macrophages to the osteoclast lineage. J Biol Chem 281: 4678-4690